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Abstract: The diagnostic accuracy of point-of-care (PoC) applications may be compromised in individuals 
with additional inflammatory conditions. This cross-sectional study examined the performance of a 
commercial oral rinse active matrix metalloproteinase-8 (aMMP-8) PoC immunotest in individuals with (n = 
47) and without Crohn’s disease (CD) (n = 41). Oral rinse collected from the participants was analyzed by the 
PoC immunotest. Molecular forms and fragments of salivary MMP-8 were detected by western 
immunoblotting. The sensitivity of the immunotest for periodontitis was 60.0% in the CD group and 90.0% in 
the control group. The respective specificity was 75.0% and 80.0%. In both groups, clinical diagnosis of 
periodontitis exhibited a significant association with the immunotest results, however, the odds ratio (OR) 
was more than ten-fold in controls (OR 54.3, 95% CI: 3.1–953, p = 0.006) in comparison to CD patients (OR 5.2, 
95% CI: 1.3–21.6, p = 0.022). According to Western immunoblot results, the immunotest MMP-8 positivity was 
not related to elevated levels of molecular forms and fragments of MMP-8 in the CD group, as in the control 
group. The diagnostic accuracy of the aMMP-8 PoC oral rinse immunotest is reduced in CD patients, which 
may be related to lower levels or undetectable complexes. 
Keywords: collagenases; Crohn’s disease; dental caries; mouth; periodontitis 
 
1. Introduction 
Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract, involving a 
complex interplay between genetic risk, environmental exposures, the microbiota, and the immune 
system. Individuals suffering from CD seem to be prone to developing periodontitis, caries, and oral 
mucosal lesions [1–3]. CD patients have a higher decayed-missed-filled teeth (DMFT) index than 
healthy individuals, which could be due to differences in their diet [3]. Indeed, CD patients 
reportedly exhibit an increased sugar consumption and have insufficient oral hygiene [4]. The 
suggested link between CD and periodontitis may be explained by shared pathways in their 
pathogenesis related to altered gut/oral microbiota [5,6] and immune responsiveness [7]. Both CD 
and periodontitis have been linked to a disrupted immunological response to the local microbiota. 
The innate immune system, particularly neutrophils and their inadequate function, plays a major role 
in the pathogenesis of these diseases [8–10]. Of tissue-degrading matrix metalloproteinases (MMPs), 
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MMP-8 is the key inflammatory mediator in their inter-relationship; elevated MMP-8 levels have 
been detected in CD patients both in the intestine and in the oral cavity [11,12]. 
Periodontitis is diagnosed based on clinical signs of gingival bleeding, loss of clinical attachment, 
deepened periodontal pockets, and the presence of radiographical alveolar bone loss [13,14]. Yet, the 
use of these parameters carries limitations, since they do not recognize the onset of inflammation or 
identify individuals who are at risk of disease initiation or progression in a given population [15]. 
Instead, biomarker-based diagnostic methods are less laborious, non-invasive, and do not require 
trained dentists, being especially useful in studies with large study populations [16]. 
In periodontology, point-of-care (PoC) tests aim to detect periodontal diseases by analyzing the 
levels of biomarkers in oral fluids (saliva, oral rinse, and/or gingival crevicular fluid) without need 
of a laboratory [17,18]. Among the tested biomarkers, salivary and oral rinse levels of MMP-8 are 
shown to be effective in distinguishing periodontitis patients from periodontally healthy individuals 
[19–21]. For instance, PoC tests using active MMP (aMMP)-8 as a diagnostic marker with a threshold 
of 20 ng/mL can successfully identify periodontitis with 64–95% sensitivity and 60–100% specificity 
[22–25]. Notably, the test sensitivity improves in line with disease severity [22,24]. 
To date, no data exist on the performance of the selected oral rinse aMMP-8 PoC immunotest in 
individuals with compromised immune responsiveness. In the present case-control study, we 
hypothesized that CD, a systemic condition with impaired immune function, leads to decreased 
sensitivity and specificity of the PoC immunotest. Our aim was to evaluate the utility of the 
immunotest for chair-side diagnostics of periodontal disease in subjects with and without CD. As a 
main conclusion, we state that the accuracy of the immunotest was impaired in individuals with CD. 
2. Materials and Methods 
2.1. Study Design and Enrolment of Participants 
This was a case-control study conducted at the Institute of Dentistry, University of Turku, from 
January 2017 to May 2018. The CD group, consisting of 47 CD patients between the ages of 22 and 77 
years, was recruited from a Crohn and Colitis patient organization (IBD Association of Finland). Their 
diagnosis of CD had previously been confirmed by endoscopy and histopathological analysis of 
intestinal biopsy specimens. The control group, including 41 age- and gender-matched individuals 
without CD or other immune-related diseases, was recruited using advertisements placed at the 
Institute of Dentistry, University of Turku. Exclusion criteria for both groups included diabetes 
mellitus, smoking, excessive use of alcohol, less than 24 teeth, and the use of antimicrobial medication 
in the preceding six months prior to the clinical examination. In addition, individuals with 
periodontitis as a manifestation of systemic disease [26] as well as pregnant or lactating women were 
excluded. 
The research protocol was approved by the Ethical Committee of the Hospital District of 
Southwest Finland (114/1801/2016), and the study was conducted according to the guidelines of the 
World Medical Association Declaration of Helsinki. Each participant was informed of the purpose, 
potential side effects and benefits of the study and gave their written consent. A structured 
questionnaire was collected from all participants regarding their demographic data (such as age, sex, 
and residence), general health, medications, and previous dental care. Additionally, the short Crohn’s 
disease activity index (CDAI) was used to assess the disease activity of the CD patients [27]. 
2.2. Clinical Oral Examination 
The full-mouth clinical examination included registrations of oral mucosal status performed by 
a specialist in oral pathology (JR) together with cariological and periodontal measurements generated 
by a periodontist (MG). Before this study, the intra-examiner (MG) agreement was tested in double 
measurements of 10 patients and discovered to be very good. 
The oral mucosal examination included visual inspection of the lips, mucous membranes of the 
oral cavity, and oropharynx while pressing the tongue down as well as manual palpation of the neck. 
All mucosal findings were described by clinical appearance and the site of the lesion. CD-associated 
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mucosal lesions (sulcular ulceration, aphthous stomatitis, mucosal cobblestone appearance, lip 
swelling, angular cheilitis, mucogingivitis) were registered separately [28,29]. 
Cariological status was assessed based on visual inspection, fiber-optic transillumination and 
tactile examination on the five surfaces of each tooth. Additionally, initial caries lesions together with 
other hard tissue defects on tooth surfaces, such as erosion and attrition, were determined. Caries 
prevalence in the whole dentition (excluding the third molars) was expressed using the decayed-
missed-filled surface (DMFS) index. The participants were classified as having caries when they had 
at least one tooth surface with a carious lesion. 
Periodontal status was obtained from six sites per each natural tooth and dental implant using 
a WHO probe (LM-Instruments Oy, Parainen, Finland) with a ball-tip end diameter of 0.5 mm. A full-
mouth dichotomous visible plaque index (VPI) score was recorded as percentage. Gingival recession 
(REC) was detected as the distance between the cemento-enamel junction and free gingival margin, 
while probing pocket depth (PPD) was measured from the free gingival margin to the most apical 
penetration point of the probe. Loss of clinical attachment level (CAL) was determined as the sum of 
REC and PPD. A full-mouth dichotomous gingival bleeding score was obtained upon bleeding on 
probing (BOP) and presented as percentage. In addition, furcation defects and tooth mobility scores 
were recorded. 
Individuals with BOP < 15%, PPD < 4 mm, and no loss of CAL were regarded as periodontally 
healthy, whereas gingivitis was diagnosed in the presence of BOP ≥15% without periodontal pockets 
and loss of CAL [30]. The diagnostic criteria for periodontitis included PPD ≥ 4 mm and/or loss of 
CAL on ≥ 2 non-adjacent teeth together with BOP [31]. The severity of the disease was classified based 
on PPD and loss of CAL as follows: initial periodontitis (PPD 4 mm, CAL loss 1–2 mm), moderate 
periodontitis (PPD 5-6 mm, CAL loss 3–4 mm), and severe periodontitis (PPD ≥ 7 mm, CAL loss ≥ 5 
mm). After the clinical examination, the patient was informed both orally and in written form of the 
findings. The patients with need for treatment were advised to contact their own dentist. 
2.3. Application of an Oral rinse aMMP-8 PoC Immunotest 
The study participants were instructed to avoid tooth brushing, eating, and chewing gum 30 
min prior to the visit. Oral rinse sampling was performed before the clinical oral examination. First, 
each participant pre-rinsed the mouth with tap water for 30 s and then spitted out or swallowed the 
fluid. After 60 s of waiting, they re-rinsed vigorously the mouth with 5 mL of rinsing fluid‡ for 30 s 
and then poured the entire sample into a measuring cup, from which the sample was drawn up into 
a syringe and used for the aMMP-8 PoC analysis. 
The immunotest (PerioSafe® PRO, Dentognostics GmbH, Jena, Germany) was used according to 
the manufacturer’s instructions. A single examiner (UKG) ran all tests, and the result was interpreted 
by visual estimation 5 min after testing. The outcome was defined as positive (+) when a double line 
(i.e., both test and control line) was visible on the test window or negative (−) when only a single line 
was observed [22]. 
2.4. MMP-8 Western Immunoblot 
Stimulated saliva samples were collected for 5 min from the patients, separately from the 
immunotest. A modified enhanced chemiluminescence (ECL) western blotting kit (GE Healthcare, 
Amersham, UK) was used to detect the molecular forms of MMP-8 from the stimulated saliva as 
described earlier [32,33]. Salivary flow levels were measured to minimize the variations in sample 
collection and sample loading during immunoblottings. Briefly, the saliva samples were mixed with 
Laemmli’s buffer without any reducing reagents. The samples were heated for 5 min, followed by 
protein separation with 11% sodium dodecyl sulphate (SDS)-polyacrylamide gels. The proteins were 
then electro-transferred onto nitrocellulose membranes (Protran, Whatman GmbH, Dassel, 
Germany). Milk powder (5%; Valio Ltd., Helsinki, Finland) was used to block non-specific binding 
in TBST buffer (10 mM Tris-HCl, pH 7.5, containing 22 mM NaCl and 0.05% Triton-X) for 1 h. The 
membranes were incubated with polyclonal primary antibodies anti-MMP-8 [34] overnight and 
followed by the horseradish peroxidase-linked secondary antibody (GE Healthcare, 
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Buckinghamshire, UK) for 1 h. The target proteins were visualized using the ECL system, and 
scanned and converted into arbitrary units (relative levels of mean intensity) using GS-700 Imaging 
Densitometer Scanner (BioRad, Hercules, CA, USA) and Bio-Rad Quantity One program. Purified 
human activated MMP-8 (BioTeZ, Berlin, Germany) was used as positive control and low range 
prestained SDS-PAGE Standards (BioRad) served as a molecular weight marker. 
2.5. Statistical Analyses 
All statistical analyses were performed using the SPSS statistical program (version 24.0; IBM Inc., 
Armonk, NY, USA). The Chi square test was used for comparing demographic and clinical data (with 
the exception of age and number of teeth) between the CD and control groups. Age, salivary flow 
rate, and number of teeth were compared between the groups with one-way ANOVA test. 
Multinomial regression analyses were performed to describe the associations between periodontal 
diseases and the immunotest result, after adjusting for furcation and attrition defects. Statistical 
significance was defined as p < 0.05. 
3. Results 
3.1. Crohn’s Disease Status 
Of the 47 CD patients, 89.4% received medication for CD and 34.0% had undergone surgical 
treatment for CD. According to the short CDAI score, 53.2% of the subjects were in remission (short 
CDAI < 150 points), 31.9% had mild disease (short CDAI 150–219 points), 14.9% had moderate disease 
(short CDAI 220–450 points), and none had severe disease (CDAI > 450 points). 
3.2. Oral Health Status 
Characterization of the CD and control groups on the basis of periodontal findings is presented 
in Table 1. 
Table 1. Characterization of the study groups (patients with Crohn’s disease and their age- and 
gender-matched healthy controls) according to periodontal health status and stimulated salivary 
flow. PPD = probing pocket depth; BOP = bleeding on probing. 
Findings 
Crohn’s Disease 
Group (N = 47) 
Control Group (N = 
41) 
Difference P-
Value 
Gender (male %) 23.4 29.3 0.629 
Age, years (mean, st.dev) 46.4 (13.9) 47.4 (13.2) 0.734 
No. of teeth (mean, st.dev) 27 (2.3) 27.6 (2.4) 0.192 
VPI % (mean, st.dev) 23.8 (20.8) 22.9 (18.7) 0.828 
BOP % (mean, st.dev) 32.7 (23.3) 33.9 (28.6) 0.820 
Individuals with PPD 4 mm (n, %) 22 (46.8) 13 (31.7) 0.192 
Individuals with PPD 5–6 mm (n, %) 1 (2.1) 8 (19.5) 0.011 
Individuals with PPD ≥ 7 mm (n, %) 0 5 (12.2) 0.019 
Individuals with REC ≥ 1 mm (n, %) 33 (70.2) 28 (68.3) 1.000 
Individuals with REC ≥ 3 mm (n, %) 14 (29.8) 12 (29.3) 0.073 
Periodontal diagnosis   0.021 
Periodontally healthy (n, %) 12 (25) 15 (36.6)  
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Table 1. Cont. 
Gingivitis (n, %) 20 (42.6) 15 (36.6)  
Initial periodontitis (n, %) 14 (29.8) 4 (9.8)  
Moderate periodontitis (n, %) 1 (2.1) 2 (4.9)  
Severe periodontitis (n, %) 0 (0) 5 (12.2)  
Stimulated salivary flow, ml/min (mean, st.dev)  1.42 (0.72) 1.59 (0.90) 0.313 
The DMFS index was 35.8 for the CD patients and 23.9 for the controls (p = 0.015). At least one 
dentin caries lesion was found in 31.9% of the CD patients and 12.2% of the controls (p = 0.028). The 
mean stimulated salivary flow was 1.42 mL/min and 1.59 mL/min, respectively. CD-associated 
mucosal lesions were detected in 10.6% of the CD patients. Mucosal lesions not associated with CD 
were found in 34.0% of the CD patients and 36.6% of the controls. 
3.3. Oral Rinse aMMP-8 PoC Immunotest 
The outcomes of the aMMP-8 PoC immunotest were tested against various clinical outcomes 
and diagnoses in terms of its sensitivity and specificity as presented in Table 2. Sensitivity and 
specificity values of the aMMP-8 PoC immunotest for detecting periodontitis were 60.0% and 75.0% 
in the CD patients, 90.9% and 80.0% in the controls, and 73.1% and 77.4% in the whole population, 
respectively. 
Table 2. Sensitivity and specificity of the oral rinse active matrix metalloproteinase-8 oral rinse point-
of-care immunotest in relation to the presence of probing pocket depth (PPD), bleeding on probing 
(BOP), furcation defects, attrition, periodontal diseases (gingivitis or periodontitis), and periodontitis. 
(- = no individuals with PPD ≥ 7 mm) 
Periodontal findings 
Sensitivity / 
Spesificity 
Crohn’s disease Group Control Group Whole Population 
  (N = 47) (N = 41) (N = 88) 
PPD 4 mm Sensitivity 54.5 84.6 65.7 
 Specificity 80 82.1 81.1 
PPD 5–6 mm Sensitivity 100 87.5 88.9 
 Specificity 65.2 72.7 68.4 
PPD ≥ 7 mm Sensitivity - 100 100 
 Specificity - 69.4 66.3 
BOP ≥ 15% Sensitivity 37.1 57.7 45.9 
 Specificity 66.7 93.3 81.5 
Furcation defect Sensitivity 40 66.7 54.5 
 Specificity 64.9 72.4 68.2 
Attrition Sensitivity 52.4 38.9 46.2 
 Specificity 76.9 60.9 69.4 
Periodontal diseases Sensitivity 35.3 57.7 45 
 Specificity 61.5 93.3 78.6 
Periodontitis Sensitivity 60 90.9 73.1 
 Specificity 75 80 77.4 
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The results of the aMMP-8 PoC immunotest were significantly associated with the diagnosis of 
periodontitis in the CD patients (OR: 5.2, 95% CI: 1.26–21.6, p = 0.022), in the controls (OR: 54.3, 95% 
CI: 3.09–953, p = 0.006), and in the whole population (OR: 8.5, 95% CI: 2.88–25.3, p < 0.001), as shown 
in Table 3. 
Table 3. Unadjusted and adjusted (furcation defects and attrition) associations of the selected oral 
rinse active matrix metalloproteinase 8 point-of-care immunotest with periodontal diseases (gingivitis 
or periodontitis) or with periodontitis. Data are given as odds ratio (95% confident intervals), and p-
value. 
Group Periodontal Diseases Periodontitis 
 Unadjusted Adjusted Unadjusted Adjusted 
Crohn’s disease group 
(N = 47) 
0.9 (0.23–3.26), 
0.84 
1.3 (0.29–
5.58), 0.752 
4.5 (1.22–16.6), 
0.024 
5.2 (1.26–21.6), 
0.022 
Control group (N = 41) 19.1 (2.17–167), 
0.08 
20.4 (1.92–
216), 0.012 
40 (4.25–376), 
0.001 
54.3 (3.09–953), 
0.006 
Whole population (N = 
88) 
3.0 (1.06–8.45), 
0.038 
4.16 (1.34–
12.9), 0.014 
9.3 (3.25–26.6), 
<0.001 
8.5 (2.88–25.3), 
<0.001 
3.4. MMP-8 Immunoblot 
Figure 1 presents the relative levels of molecular forms, activations, and fragments of MMP-8 in 
saliva. 
 
Figure 1. Western immunoblot analysis of salivary samples studied for molecular forms, degree of 
activation and related fragmentation of matrix metalloproteinase (MMP)-8. “PMN” indicates 
neutrophil-type collagenase (70–80 kDa) and “Mes” fibroblast-type MMP-8 collagenase (50–65 kDa) 
together with their pro and active forms. “Complexes” indicate multiple forms of MMP-8 (>110 kDa) 
and “fragments” the fragmented MMP-8 species (20–30 kDa). Lanes 1 and 2 illustrate the Crohn’s 
disease group, and lanes 3 and 4 the control group. All laboratory conditions (incl. time of exposure) 
and image analyses were standardized. Purified human activated MMP-8## was used as positive 
control (lane 5). Mobilities of the molecular weight markers (low range prestained SDS-PADE 
Standards (Bio-Rad Laboratories, Inc, Richmond, CA, USA) are indicated on the left. 
According to the immunoblot results, in the control group the PoC immunotest positivity is 
related to elevated levels of different forms and fragments of MMP-8 in saliva (Table 4). In CD 
patients, however, no difference in the levels of salivary forms of MMP-8 was observed between the 
PoC immunotest positive and negative individuals. 
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Table 4. Relative levels of mean intensity (median, min-max) of molecular forms and fragments of 
salivary MMP-8 as regards to oral rinse point-of care immunotest positivity (+) and negativity (−). p 
values indicating a significant difference (<0.05) are bolded. 
Group 
Complexes 
of MMP-8 
PMN Mesenchymal Fragments 
of MMP-8 
Total 
MMP-8 Pro 
MMP-8 
aMMP-8 Pro 
MMP-8 
aMMP-8 
Crohn’s 
disease Group 
+ (N 
= 17) 
1.8 (0.6–
4.1) 
0.4 (0.1–
2.1) 
0.0 (0.0–
1.2) 
0.6 (0.0–
1.5) 
0.5 (0.0–
1.6) 
0.1 (0.0–
1.4) 
3.8 (1.0–
9.5) 
− (N 
= 30) 
1.5 (0.2–
4.2) 
0.4 (0.0–
1.1) 
0.1 (0.0–
1.3) 
0.8 (0.0–
1.6) 
0.8 (0.0–
1.7) 
0.6 (0.0–
0.5) 
3.7 (1.5–
8.2) 
P 0.330 0.877 0.708 0.303 0.061 0.192 0.982 
Control Group + (N 
= 16) 
1.4 (0.1–
4.7) 
0.6 (0.0–
1.5) 
0.4 (0.0–
1.4) 
1.0 (0.1–
1.8) 
0.9 (0.0–
1.9) 
0.1 (0.0–
2.4) 
4.9 (0.4–
11.8) 
− (N 
= 25) 
0.5 (0.0–
3.7) 
0.2 (0.0–
1.8) 
0.0 (0.0–
1.0) 
0.6 (0.0–
1.6) 
0.7 (0.0–
1.7) 
0.0 (0.0–
0.5) 
2.2 (0.2–
7.6) 
P 0.022 0.037 0.015 0.121 0.209 0.046 0.015 
Whole 
Population 
+ (N 
= 33) 
1.6 (0.1–
4.7) 
0.4 (0.0–
2.1) 
0.1 (0.0–
1.4) 
0.8 (0.0–
1.8) 
0.2 (0.0–
1.9) 
0.1 (0.0–
2.4) 
3.9 (0.4–
11.8) 
− (N 
= 55) 
1.0 (0.0–
4.2) 
0.3 (0.0–
1.8) 
0.5 (0.0–
1.3) 
0.7 (0.0–
1.6) 
0.7 (0.0–
1.7) 
0.1 (0.0–
0.5) 
3.1 (0.2–
8.2) 
P 0.032 0.174 0.140 0.670 0.689 0.020 0.062 
4. Discussion 
To our knowledge, this is the first study to investigate the sensitivity and specificity of a 
chairside diagnostic kit in detection of periodontitis in patients with disrupted immune 
responsiveness. Our findings demonstrate that both the sensitivity and specificity of the aMMP-8 oral 
rinse PoC immunotest are significantly impaired in CD patients. 
A comprehensive examination of periodontal, cariological, and oral mucosal health is the 
strength of the present study. Although there was no significant decrease in salivary flow in the CD 
group, the DMFS index was significantly higher in CD patients than in controls. Only 25% of the CD 
patients were periodontally healthy compared to 37% of the control group. In addition, CD patients 
presented more gingivitis and initial periodontitis than their generally healthy controls. These clinical 
findings are in line with several previous studies indicating differences in caries and periodontal 
states of CD patients in comparison to systemically healthy individuals [1–3]. On one hand, a higher 
DMF index may be attributed to nutritional and behavioral changes, such as an increased intake of 
carbohydrates and alterations in bacterial conditions in the oral cavity favoring mutans streptococci 
and lactobacilli [4,34,35], although these factors were not examined in the present study. On the other 
hand, the association between CD and periodontitis has been attributed to common predisposing 
factors, including age, genetic predisposition, and lifestyle factors, but perhaps more importantly to 
defects in the mucosal barrier, disrupted immune responses, and the exuberant host-response to 
bacteria leading to chronic inflammation [36]. Moreover, CD patients seem to exhibit a higher 
prevalence and more generalized and more severe periodontitis than non-CD individuals [2,3,37,38]. 
Contrarily, in the present study, severe periodontitis (12%) was diagnosed only in the control group. 
The small group size may have an impact on the results, but it was not possible to expand the present 
study sample size due to the low prevalence of Crohn’s disease. The cross-sectional study design is 
another limitation of the present study, and thus, we cannot infer any temporal association between 
CD and oral disease. Moreover, the recruitment of the control group was in part undertaken at a 
dental clinic, which may result in a selection bias. However, this does not weaken the associations 
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between the outcomes of the chairside test and periodontitis diagnosis after adjusting for clinical 
parameters. 
The PoC oral rinse and salivary tests can be used as noninvasive and economic methods for 
screening and diagnosing disease. Various inflammatory proteins present in saliva have been tested 
as candidate biomarkers for periodontitis [39–43]. For example, salivary MMP-8 can be detected in 
different isoforms based on its origin (neutrophilic or mesenchymal type) or molecular forms (active, 
pro-, fragmented, complex) [32,33]. Moreover, neutrophils, fibroblasts, and endothelial cells are the 
main sources of MMP-8 in the oral cavity [44,45]. Some studies have indicated that dental caries has 
an impact on oral MMP-8 levels, and thereby, caries lesions may affect the outcome of oral rinse 
aMMP-8 PoC immunotests [22,46]. The causal relationship between caries and salivary MMP-8 has 
not been established, but the association between the number of cariotic lesions and MMP-8 levels 
suggests a role for the collagenase in the dentin caries process [46]. In our study, the sensitivity and 
specificity of the kit for caries detection in the whole population were low, 55.0% and 67.6%, 
respectively. One explanation for this could be the activity of the cariotic process. In comparison to 
chronic or stable caries lesions, active lesions seem to correlate more with MMP activity [47]. In 
addition, open caries lesions may more likely cause leakage of MMPs into the saliva in comparison 
to non-cavitated small caries lesions [47]. 
Recent research has shown promising results regarding the use of aMMP-8 as a diagnostic 
biomarker in PoC oral rinse tests for periodontitis [22–25,43,48]. The oral rinse aMMP-8 PoC 
immunotest, also used in the present study, applies lateral flow chromatography and detects the 
active form of MMP-8 with targeted antibodies [43,48]. A positive result of the test is based on a cutoff 
of 20 ng/mL for aMMP-8, and it can identify periodontitis with 64–95% sensitivity and 60–100% 
specificity [22–25]. In comparison to salivary MMP-8 analyses, the oral rinse aMMP-8 PoC 
immunotest has demonstrated a higher accuracy when differentiating periodontal health from the 
disease [43,48]. However, little information is still available regarding the limitations of this test. 
There are common and discordant elements in the pathogenesis of CD and periodontitis. Indeed, 
both disorders lead to a substantial defect in the mucosal barrier and exuberant host response to 
bacteria, resulting in inflammation and tissue destruction. It is reasonable to speculate that the 
dysregulation of the immune system in CD may have an effect on MMP-8 levels in the oral cavity. It 
has been shown in a mouse model simulating inflammatory bowel disease that inflammation in the 
colon changes the microbiota not only in the colon but also in the oral cavity [9]. In the current study, 
the sensitivity and specificity estimates of the aMMP-8 PoC immunotest for detecting periodontitis 
were found to be poorer in CD patients (60.0% and 75.0%) than in systemically healthy controls 
(90.9% and 80.0%). The reasons for this are most likely multifactorial. Firstly, it can be argued that the 
prescribed immunomodulatory or anti-inflammatory medications affect the test accuracy. However, 
these medications act as suppressors of inflammatory response, which means that both clinical and 
sub-clinical indices of periodontitis (i.e., bleeding on probing as well as MMP-8 expression and 
activation, respectively) can be restrained. Thus, the use of medications does not fully explain the low 
sensitivity and specificity values of aMMP-8 PoC test in periodontitis patients with Crohn’s disease. 
Secondly, impaired neutrophil MMP-8 function might be another explanation for the low sensitivity 
of the test in CD patients. Our western immunoblot experiment of salivary MMP-8 indicated that the 
aMMP-8 PoC oral rinse immunotest positivity in the CD group does not reflect the changes in the 
levels of molecular forms and fragments of MMP-8, varying from that observed in the control group. 
The difference may be explained, at least in part, by genetics. Indeed, a mutation in the nucleotide-
binding oligomerization domain 2/caspase recruitment domain 15 (NOD2/CARD15) gene, which 
impairs the ability to recognize bacterial components and thus triggers an inadequate immune 
response, has been reported in patients with CD [49]. Interestingly, when patients suffering from 
rheumatoid arthritis - another example of a disease with dysregulated immune system - were 
compared to systemically healthy periodontitis patients, they exhibited increased aMMP-8 levels in 
gingival crevicular fluid [50]. Additionally, in presence of vascular leakage components in saliva 
samples, alpha 2-macroglobulin may form complexes with proteases, which in turn may partly 
explain the high-molecular weight complexes [51]. Formation of these complexes, however, may not 
Biomolecules 2020, 10, 395 9 of 12 
totally explain the current results, since all samples were free of blood contamination. Finally, all 
these observations indicate that patients with a systemic disease manifested with impaired immune 
responsiveness need to be evaluated in a disease-specific manner before any diagnostic test can be 
reliably utilized. The reasons why 1) MMP-8 is not a functioning biomarker in CD patients or 2) 
aMMP-8 PoC immunotest seem to produce less accurate results in CD patients remain unsolved. 
Therefore, further studies are still required. 
5. Conclusions 
In conclusion, the performance of the oral rinse aMMP-8 PoC immunotest for recognizing 
periodontitis seem to be less reliable in CD patients than in systemically healthy individuals. 
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